Nymak Pharma Profile
Key Indicators
- Authorised Capital ₹ 2.65 Cr
- Paid Up Capital ₹ 5.00 M
- Company Age 10 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2.50 Cr
- Revenue Growth %
- Net Worth -31.40%
- Total Assets -25.43%
About Nymak Pharma
Nymak Pharma Private Limited (NPPL) is a Private Limited Indian Non-Government Company incorporated in India on 23 September 2014 and has a history of Ten years and five months. Its registered office is in Kachchh, Gujarat, India.
The Corporate was formerly known as Nymak Pharma Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.65 Cr and a paid-up capital of Rs 5.00 M.
The company currently has active open charges totaling ₹2.50 Cr.
Haresh Advani, Ranjit Advani, and Deepa Advani serve as directors at the Company.
Company Details
- Location
Kachchh, Gujarat, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U33110GJ2014PTC080874
- Company No.
080874
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
23 Sep 2014
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Who are the key members and board of directors at Nymak Pharma?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Haresh Advani  | Director | 23-Sep-2014 | Current |
| Ranjit Advani | Director | 23-Sep-2014 | Current |
| Deepa Advani | Director | 23-Sep-2014 | Current |
Financial Performance of Nymak Pharma.
Nymak Pharma Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth observed a substantial decline by a decrease of 31.4%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss | |||||||
| Net Worth |
| ||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Nymak Pharma?
Unlock access to Nymak Pharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
₹2.50 Cr
₹0
Charges Breakdown by Lending Institutions
- Uco Bank : 2.50 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 25 Sep 2024 | Uco Bank | ₹1.90 Cr | Open |
| 25 Sep 2024 | Uco Bank | ₹6.00 M | Open |
How Many Employees Work at Nymak Pharma?
Unlock and access historical data on people associated with Nymak Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nymak Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nymak Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
